Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5162504A · kind A · utility
197Cited by
0References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 3, 1988 |
| Grant date | Nov 10, 1992 |
| Priority date | — |
| Expiry date | Jun 3, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to normal and neoplastic, human prostate epithelial cells. The monoclonal antibodies, specifically 7E11-C5 monoclonal antibodies, may be suitable for diagnostic uses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.